<DOC>
	<DOCNO>NCT00692250</DOCNO>
	<brief_summary>This study design assess potential interaction colesevelam ciclosporin healthy volunteer .</brief_summary>
	<brief_title>A Study Assess Any Potential Interaction Between Colesevelam Ciclosporin Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Colesevelam Hydrochloride</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>Subject must body mass index ( BMI ) 19 25 inclusive Medically healthy subject clinically normal laboratory profile , physical exam , vital sign ECGs . Give voluntary write informed consent participate study History presence significant cardiovascular , pulmonary , hepatic renal , hematologic , gastrointestinal ( inclusive dysphagia , swallow disorder , severe gastrointestinal motility disorder ) , endocrine , immunologic , dermatologic , neurologic , infectious , psychiatric disease . In addition , history presence : Alcoholism drug abuse within past year ; OR hypersensitivity idiosyncratic reaction ciclosporin immunosuppressive agent ; OR Chronic infection Subjects ere test positive screening HIV , HBsAg HCV Subjects receive injectable corticosteroid 12 week precede first dose . Subjects allergic castor oil corn oil Subjects whose sit blood pressure le 110/60 mmHg screen 100/55 mmHg dose Subjects use medication substance know strong inhibitor CYP3A enzymes within 10 day prior first dose . Subjects use medication substance know strong inducer CYP3A enzymes within 28 day prior first dose . Subjects use antibiotic within 14 day prior first dose . Subjects use medication ( include overthecounter product ) vitamin herbal product within 7 day prior first dose . Subjects use live attenuated vaccine within 7 day prior first dose planning use within 14 day end study . Subjects , prior inform consent , would donate excess : 500mL blood 14 day ; 1500mL blood 180 day ; OR 2500mL blood 1 year . Subjects participate another clinical trial : within period le equal 2 half live ( t1/2 ) previous investigational product use OR within 60 day prior first dose .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Familial Hypercholesterolemia</keyword>
</DOC>